title: Rethinking biologics in lupus nephritis.
abstract: Lupus nephritis (LN) is a chronic and devastating complication of systemic lupus erythematosus. Despite advances in our understanding of LN and the availability of effective therapies, LN remains a difficult clinical problem, and progression to end stage renal disease remains a significant challenge. Though the advent of biologics has revolutionized the treatment of many rheumatological conditions, and several clinical trials of biologics have been conducted in LN, the promise of biologics remains unfulfilled. The experience gained from these initial clinical trials can help tailor approaches in future clinical trials, and the lessons learned can be applied to find a cure for this condition.
authors: Cedars-Sinai Health System - Rheumatology, USA swamy.venuturupalli@gmail.com.
authors: S
authors: S
authors: Venuturupalli
mesh_terms: D000069594:Abatacept / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D000069283:Rituximab; C511911:belimumab; D000069594:Abatacept
keywords: Systemic lupus erythematosus; biologics; clinical trials; lupus nephritis; review